共查询到19条相似文献,搜索用时 234 毫秒
1.
目的评价草酸铂(L-OHP)联合氟脲嘧啶(5-FU)、甲酰四氢叶酸钙(CF)二线治疗晚期复发大肠癌的疗效和不良反应。方法L-OHP 130 mg/m^2,静脉滴入,2 h,d1;CF 100 mg/m^2,5-FU前2小时静脉滴入,d1-d5;5-FU 500 mg/m^2,静脉滴入,6-8 h,d1-d5,21 d为1个周期。结果全组CR 1例,PR 3例,SD 17例,PD 4例,总有效率为16%,疾病控制率为84%。主要不良反应为中性粒细胞减少、消化道反应及外周神经毒性。结论L-OHP联合5-FU、CF方案(OFL)二线治疗晚期复发大肠癌安全、有效,毒性反应可耐受。 相似文献
2.
目的 探讨布拉酵母联合小剂量红霉素治疗小儿功能性消化不良(FD)的临床疗效。方法 将92例FD患者随机分为对照组(n=46)和观察组(n=46)。对照组单纯用红霉素3~5 mg/(kg•d),3次/d饭前服用。观察组在对照组治疗方法基础上联合布拉酵母0.25 g/次,2次/d,餐后口服,2周一疗程。随访6个月观察其复发率。结果 观察组总有效率(95.65%)明显高于对照组(76.09%),差异有统计学意义(P<0.01)。2组患者治疗后HAMD评分均较治疗前下降,但观察组降低幅度显著大于对照组(P<0.01)。观察组患者症状消失时间显著短于对照组,差异有统计学意义(P<0.01)。治疗后随访6个月,观察组患者复发率明显低于对照组(P<0.05)。结论 布拉酵母联合小剂量红霉素对小儿FD具有显著的临床疗效,患者的复发率较低。 相似文献
3.
目的:观察洛铂与紫杉醇联合化疗治疗晚期卵巢癌的近期疗效及不良反应。方法:50例晚期卵巢癌(Ⅲ期或Ⅳ期)患者,其中26例患者采用洛铂+紫杉醇静脉化疗,其中洛铂30mg/m2,d1天,紫杉醇135~175mg/m。dl天。24例患者采用顺铂+紫杉醇静脉化疗,其中顺铂25mg/m2,d1-3天,紫杉醇135~175mg/m。dl天,2~4个疗程观察疗效。结果:26例洛铂组患者中,完全缓解7例,部分缓解8例,稳定9例,进展2例,有效率为57.7%。24例顺铂组患者中,完全缓解5例,部分缓解8例,稳定6例,进展5例,有效率为54.2%。主要毒副反应为骨髓抑制、骨骼酸痛、神经毒性和脱发。结论:洛铂联合紫杉醇治疗晚期卵巢癌疗效较好,毒副反应可以耐受。 相似文献
4.
摘要 目的:分析信迪利单抗联合白紫+替吉奥(S-1)二线在人表皮生长因子受体2(Her-2)阴性胃癌治疗中的近远期疗效及其安全性。方法:根据随机数字表法将2018年1月~2021年1月在本院接受治疗的76例Her-2阴性胃癌患者分为对照组与观察组,每组各38例,对照组给予白紫+替吉奥二线治疗,观察组给予白紫+替吉奥二线+信迪利单抗治疗;观察两组患者的近期疗效和不良反应发生率,并在随访24个月后记录两组患者的远期疗效,Logistic多因素分析影响患者达到中位OS、PFS的独立危险因素。结果:与对照组比较,观察组ORR、DCR率较高(P<0.05);与对照组比较,观察组中位OS、PFS较高(P<0.05);Logistic多因素分析结果显示,治疗方法(白紫+替吉奥二线)是影响HER-2阴性胃癌达到中位PFS和OS的独立危险因素(P<0.05);两组不良反应发生率比较无差异(P>0.05)。结论:白紫、替吉奥二线与信迪利单抗联合治疗不仅能保障Her-2阴性胃癌治疗的安全性,还能进一步提升患者的临床治疗效果,并延长其生存期。 相似文献
5.
目的:评估交替放化疗(CRT)对晚期鼻咽癌(NPC)患者的疗效与影响因素。方法:选取在我院耳鼻喉科治疗的102例鼻咽癌患者。交替使用放疗,化疗进行治疗。在102例患者中,83例接受顺铂(50 mg/m2/d,d1-2)和5-氟尿嘧啶(5-Fu;800 mg/m2/d,d1-5),而19例患者接受卡铂(20 mg/m2/d,d6)和5-FU。结果:72(70.6%)例患者完成全部3个化疗疗程。交替放化疗的总时间为92(82-102)天。中位随访时间54个月,5年无进展生存期(PFS)为70.5%。多因素分析显示,体重减轻和化疗疗程数对PFS有显著影响。结论:化疗与放疗交替治疗的NPC患者依从性好,适应性强,值得临床推广。 相似文献
6.
目的:考察贝伐珠单抗联合化疗二线及以上治疗晚期非鳞型非小细胞肺癌的疗效和安全性。方法:28 例经病理组织学或细胞学证实的晚期非鳞型非小细胞肺癌患者接受贝伐珠单抗联合化疗的二线及以上治疗,其间,贝伐珠单抗所用剂量为7.5 mg ? kg -1,在化疗第1 d 静滴给予;化疗方案包括培美曲塞加或不加铂类、白蛋白结合型紫杉醇加或不加铂类及替吉奥以及吉西他滨/ 紫杉醇/ 多西紫杉醇加或不加铂类。各治疗方案每3 周为1 个周期,持续4 个周期,然后维持治疗,直至受试者不能耐受或疾病进展。按RECIST 1.1 版评价疗效,按NCI-CTC 4.0版评价不良反应。结果:28 例受试者中,无完全缓解病例,部分缓解11 例(39.3% ),稳定16 例(57.1% ),进展1 例(3.6% );客观缓解率为39.3% (11/28),疾病控制率为96.4% (27/28);中位无进展生存期为5 个月,中位总生存期为10 个月。亚组数据分析可见,贝伐珠单抗联合化疗各方案亚组中,培美曲塞方案受试者的中位无进展生存期为6 个月,疗效最好,较其他各方案亚组有统计学差异(P=0.028)。安全性数据分析显示,与贝伐珠单抗相关的主要不良反应有Ⅰ ~ Ⅲ度高血压以及Ⅰ / Ⅱ度蛋白尿/ 出血/ 发热。结论:贝伐珠单抗联合化疗用于二线及以上治疗晚期非鳞型非小细胞肺癌的疗效较单纯化疗有一定改善,且毒副反应可耐受,对经济上可以接受的患者值得推荐使用。 相似文献
7.
季晓军 《中国微生态学杂志》2014,(5):555-557
目的探讨双歧杆菌三联活菌胶囊联合莫沙必利治疗功能性消化不良(FD)的疗效及预防复发作用。方法选取FD患者80例,随机分为观察组和对照组。两组患者予以莫沙必利片5 mg,3次/d,连用8周。观察组患者加用双歧杆菌三联活菌胶囊420 mg,3次/d,连用8周。对照组患者除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗后的临床疗效及安全性,并比较治疗后随访6个月内的复发率。结果治疗8周后,观察组患者临床总有效率(95.0%)明显高于对照组(75.0%)(χ2=4.11,P〈0.05);观察组和对照组治疗期间出现不良反应2例和4例,症状较轻,两组不良反应发生率比较差异无统计学意义(χ2=0.18,P〉0.05)。治疗后随访6个月,观察组和对照组分别复发5例(12.5%)和13例(32.5%),观察组患者的复发率明显低于对照组(χ2=4.59,P〈0.05)。结论双歧杆菌三联活菌胶囊联合莫沙必利治疗FD的疗效肯定,安全性较好,并能明显降低其复发率,具有预防病情复发作用。 相似文献
8.
连杏飞 《中国微生态学杂志》2014,(10):1172-1174
目的探讨双歧杆菌三联活菌胶囊联合莫沙比利治疗慢性功能性便秘的疗效比较。方法选取慢性功能性便秘患者72例,采用随机数字表将患者随机分为观察组(n=36例)和对照组(n=36例)。两组患者均予以多饮水、调整饮食结构与纠正不良的饮食习惯。观察组患者予以双歧杆菌三联活菌胶囊(420mg/次,3次/d,温水口服)联合莫沙比利(5 mg/次,3次/d,餐前30 min口服)治疗,对照组患者予以单纯莫沙比利治疗,剂量与方法同观察组,两组均连用6周。观察并记录两组患者治疗后的临床效果和药物不良反应,并比较治疗后6个月和1年内的复发情况。结果治疗6周后,观察组临床总有效率为94.44%,明显高于对照组的77.78%(χ2=4.18,P〈0.05)。治疗中观察组出现不良反应3例(8.33%),对照组出现5例(13.89%),症状均较轻,未发生严重的不良反应,两组不良反应发生率比较差异无统计学意义(χ2=0.40,P〈0.05)。治疗后随访观察6个月和1年,观察组分别复发4例(11.11%)和9例(25.00%),对照组分别复发11例(30.56%)和18例(50.00%),观察组的复发率明显低于对照组(χ2=4.13和4.80,P〈0.05)。结论双歧杆菌三联活菌胶囊联合莫沙比利治疗慢性功能性便秘的效果确切,可迅速改善患者临床症状,安全性较好,并可降低其复发率,具有预防病情复发作用。 相似文献
9.
目的:培美曲塞是一种多靶点抗叶酸化疗药,目前已成为晚期非小细胞肺癌二线治疗的标准药物.本研究回顾分析培美曲塞单药或联合铂类治疗晚期复治非小细胞肺癌的疗效及不良反应.方法:对既往至少接受过1个标准含铂方案化疗的54例晚期非小细胞肺癌怠者,分为单药治疗组21例,联合铂类治疗组33例.单药治疗组给予培美曲塞单药治疗,培美曲塞500mg/m2,第1天,21天为1个周期;联合铂类治疗组给予培美曲塞联合顺铂或卡铂,培美曲塞500mg/m2,第1天,顺铂75 mg/m2或卡铂AUC=5,第1天,21天为1个周期.评价疗效及不良反应.结果:54例患者均可评价疗效.单药治疗组PR 1例,RR4.8%,SD10例,疾病控制率(DCR)52.4%,PD10例(47.6%).中位无进展生存期3.8个月;联合治疗组PR4例,RR12.1%,SD20例,疾病控制率(DCR)72.7%,PD9例(27.3%).中位无进展生存期4.8个月.与药物相关的不良反应主要为:Ⅰ/Ⅱ度骨髓抑制、胃肠道反应.结论:培美曲塞或与铂类联合治疗晚期复治非小细胞肺癌有效,不良反应轻微、可耐受. 相似文献
10.
目的:观察奈达铂(NDP)、替加氟(rt-207)联合紫杉醇(PTx)治疗晚期食管癌的近期疗效及安全性。方法:选择2008年3月至2010年6月在我院治疗的65例晚期食管癌患者,应用NDP20mg/m2,静脉滴注,第1~3天;Ft--207500mg/m2,静脉滴注射,第1~5天;PTx135~175mg/m2,静脉滴注,第1天;21天为1个周期,至少2个周期后评价疗效和毒副反应的发生情况。结果:除1例因奈达铂过敏反应停药外,共64例患者完成化疗并可评价疗效。该方案总体有效率(RR)为56.3%,其中完全缓解(CR)3例(占4.7%),部分缓解(PR)33例(占51.6%),病情稳定(SD)17例(占26.6%),另有11例(占17.2%)出现不同程度的疾病进展(PD)。仅1例出现可控制的Ⅳ度骨髓抑制。结论:NDP、Ft-207联合PTx对晚期食管癌近期疗效肯定,安全性好,值得临床推广应用。 相似文献
11.
Bodoky G 《Magyar onkologia》2003,47(2):194-197
In the first phase of this study 34 patients with advanced pancreatic cancer have been treated either with gemcitabine/cisplatin or gemcitabine/5-fluorouracil (5FU)/leucovorin combination. (Gemzar: 900 mg/m2, Cisplatin: 20 mg/m2, 5-FU: 750 mg/m2). Treatments were continued till tumor progression. There was no difference observed between the two protocols in the clinical response rates (PR=65%). On the other hand, a significant difference was found between the two protocols regarding the side effects. In the case of gemcitabine/5-FU neutropenia, thrombocytopenia and anaemia (as well as nausea and vomiting) were much less frequent compared to gemcitabine/cisplatin combination. Based on these data the efficacy of gemcitabine/5-FU combination was evaluated in 99 stage III, T1-4, N1 and stage IV, T1-4, N0-1, M1 pancreatic cancer patients throughout 364 treatment cycles. OR was achieved in 10% while stable disease in 52% of the cases. The average survival period was 8.33 months while the time to progression was 5.75 months. Based on these data we recommend gemcitabine/5-FU/leucovorin combination for the treatment of advanced pancreatic cancer. 相似文献
12.
目的:比较诺维本联合希罗达方案(NF方案)和紫杉醇联合顺铂方案(TP方案)治疗晚期乳腺癌的疗效及安全性。方法:将117例经病理证实的晚期乳腺癌患者随机分为两组,第一组66例采用紫杉醇135mg/m~2,第1天静点,顺铂20mg,第2-6天静点,21天为一个周期。第二组51例采用诺维本25mg/m~2,第1,8天静点,希罗达2500mg/m~2,每天2次,连服14天,21天为一个周期。两组均以三个周期为一个疗程,至少接受两个疗程化疗。结果:TP组总有效率为42-4%(28/66);NF组为60.8%(31/51),p<0.05。TP组中位无进展时间7.7个月,中位生存时间为16.6个月。NF组分别为10.3个月和22.1个月,p<0.05。恶心呕吐的发生率NF组明显低于TP组,p<0.05。其余不良反应发生率相近,p>0.05。所有不良反应均能耐受。结论:诺维本联合希罗迭方案疗效较好,可作为晚期乳腺癌首选治疗方案。 相似文献
13.
目的:探讨注射液胸腺法新(日达仙)辅助希罗达联合奥沙利铂治疗晚期胃癌的临床疗效和对患者免疫功能及生活质量的影响。方法:选择2010-2013入院治疗的晚期胃癌患者116例,随机平均分为实验组(58例)和对照组(58例)。对照组给予卡培他滨片(希罗达)联合奥沙利铂,试验组在对照组的基础上辅用注射液胸腺法新(日达仙)治疗。每治疗两到三个周期后进行一次系统疗效评估,评估项目包括影像学腹部CT、胸片、腹部彩超、血常规、尿常规、肝功、肾功,肿瘤标记物癌胚抗原(CEA)、糖类抗原(CA19-9,CA72-4)、免疫指标CD3+、CD8+、CD4/CD8、NK细胞,总治疗周期为6-8个周期。结果:实验组疾病治疗有效率为48%,对照组有效率为29%,两组比较差异具有统计学意义(p=0.041),实验组患者中位无疾病进展期(PFS)为12.5月,显著高于对照组10.1月,两组比较具有统计学意义(P0.05)。实验组患者生活质量评分、外周血CD3+、CD8+、CD4/CD8、NK细胞数量均显著优于对照组(P0.05)。结论:注射液胸腺法新(日达仙)辅助希罗达联合奥沙利铂(XELOX方案)能够提高晚期胃癌的临床疗效,改善患者的生活质量和免疫力,减少患者化疗用药的毒副反应。 相似文献
14.
Clinical trials on efficacy and toxicity of combined use of bleomycetin, 5-fluorouracil and cisplatin in patients with disseminated tumor processes were conducted. Two regimens were applied. Regimen I included intravenous administration of cisplatin in a dose of 100-150 mg/m2 on day 1, intramuscular administration of bleomycetin in a dose of 10 mg on days 2-4 and intravenous jet injection of 5-fluorouracil in a dose of 400 mg/m2 on days 2-4. Regimen II consisted of intramuscular administration of bleomycetin in a dose of 10 mg on days 1-3, intravenous jet injection of 5-fluorouracil in a dose of 400 mg/m2 on the same days and intravenous administration of cisplatin in a dose of 100-150 mg/m2 on day 4. The intervals between the courses amounted to 4 weeks. Complete regression of cervical carcinoma relapsing was observed in 1 patient. In 5 patients i.e. 1 with small-cell lung cancer, 3 with squamous cell lung cancer and 1 with metastases of low-differentiated cancer from an undetected focus to supraclavicular lymph nodes the effect was partial. Long-term stabilization of the disease at the background of the treatment for 6-7 months was stated in 3 patients. On the whole the objective response was in 6 out of 22 patients or in 27 per cent. 7 of them were treated with cisplatin in a dose of 150 mg/m2. The regimens of the combined use of 5-fluorouracil, bleomycetin and cisplatin were low toxic. The therapeutic effect showed that the combination was of practical value. 相似文献
15.
目的:探讨紫杉醇(PTX)、长春瑞滨(NVB)两药与顺铂(DDP)联用方案对晚期乳腺癌的临床疗效及副反应。方法:将2009年2月至2014年2月于我院就诊的60例晚期乳腺癌患者随机分为TP方案和NP方案两组,每组30例。TP方案组:顺铂25mg/m2,d1~d3,紫杉醇175 mg/m2,d1;NP方案组:顺铂25 mg/m2,d1~d3,长春瑞滨25 mg/m2,d1和d8。比较两组患者的临床有效率并记录相关不良反应。结果:TP方案有效率56.7%(17/30),中位缓解期7.5个月。NP方案有效率53.3%(14/30),中位缓解期7.7个月。组间疗效及缓解期差异无统计学意义(P0.05)。TP与NP方案组出现血小板减少、白细胞减少、贫血、恶心呕吐的发生率分别为26.7%、76.7%、56.7%、43.3%和26.7%、76.7%、56.7%、43.3%,两方案血液毒性差异无统计学意义(P0.05)。静脉炎及关节肌肉反应的发生率分别为30.0%、13.3%和16.7%53.3%,差异有统计学意义(P0.05)。结论:紫杉醇、长春瑞滨与顺铂联用治疗晚期乳腺癌疗效相当,不良反应可耐受,都可做为晚期乳腺癌治疗的一线用药方案。 相似文献
16.
S Basu M Khanra B Dash J Majumdar J Biswas P Chaudhuri 《Cancer immunology, immunotherapy : CII》1999,16(3):199-203
We performed a retrospective analysis on the effect of neoadjuvant chemotherapy with three cycles of methotrexate (100 mg/m2 on day 1), cisplatin (90 mg/m2 on day 1) and bleomycin (20 mg/m2 on day 1–5) with 21 d gap between each cycle in 44 patients with advanced squamous cell carcinoma of the cheek, lip and tongue
followed by surgery and adjuvant chemotherapy consisting of cisplatin (90 mg/m2 on day 1), Mitomycin C (6 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 120 h continuous infusion from day 1) repeated every 3 weeks for three cycles.
Following induction chemotherapy, complete response was observed in 11 out of 44 patients (25%), and a partial response in
a further 28 patients (64%).
The overall median survival of all patients was 29 months and those in stage III and stage IV were 30 and 15 months respectively
(P<0.001). The median duration of the time to relapse in patients who responded to adjuvant chemotherapy was 28 months.
The main toxic effect was vomiting followed by hematological toxicity. No treatment-related deaths occurred.
The regimen showed a significant response, encouraging median survival and a good tolerability profile. 相似文献
17.
茅慧石燕王治宽吕瑶戴广海 《现代生物医学进展》2012,12(15):2959-2961
目的:观察贝伐单抗二线治疗转移性结直肠癌患者的临床疗效和毒副反应。方法:回顾性分析2008年8月至2011年10月我院经组织病理学证实的转移性结直肠癌患者21例,一线治疗进展后,二线治疗方案中加用贝伐单抗,用法为5mg/kg,每2-3周1次,与化疗方案同步。化疗方案以奥沙利铂及伊立替康为基础,完成2-3周期治疗后评定疗效,观察毒副反应。结果:21例患者中PR1例,SD11例,PD9例,客观缓解率为4.8%,疾病控制率为57.1%,中位TTP为3.7个月。患者出现的不良反应有骨髓抑制、皮疹、恶心呕吐、腹泻、肝功能损害、神经毒性等,贝伐单抗所致高血压的发生率为14.3%(3/21),鼻衄发生率为4%(2/21)。结论:二线治疗中使用贝伐单抗,对一线治疗进展后的转移性结直肠癌疗效有限,毒副反应可耐受。 相似文献
18.
Brodie AH Jelovac D Long B 《The Journal of steroid biochemistry and molecular biology》2003,86(3-5):283-288
Aromatase inhibitors have now been approved as first-line treatment options for hormone-dependent advanced breast cancer. When compared to tamoxifen, these aromatase inhibitors provide significant survival and tolerability advantages. However, the optimal use of an aromatase inhibitor and tamoxifen remains to be established. To date, the intratumoral aromatase xenograft model has proved accurate in predicting the outcome of clinical trials. Utilizing this model, we performed long-term studies with tamoxifen and letrozole to determine time to disease progression with each of the treatment regimens. Aromatase-transfected MCF-7Ca human breast cancer cells were grown as tumor xenografts in female ovariectomized athymic nude mice in which androstenedione was converted to estrogen and stimulated tumor growth. When tumor volumes were approximately 300 mm3, the animals were grouped for continued supplementation with androstenedione only (control) or for treatment with letrozole 10 μg per day (long-term), tamoxifen 100 μg per day (long-term), letrozole alternating to tamoxifen (4-week rotation), tamoxifen alternating to letrozole (4-week rotation), or a combination of the two drugs. Tumors of control mice had doubled in volume in 3–4 weeks. In mice treated with tamoxifen and the combination, tumor doubling time was significantly shorter (16 and 18 weeks, respectively) than with letrozole (34 weeks). Furthermore, alternating letrozole and tamoxifen treatment every 4 weeks was less effective than letrozole alone. Tumors doubled in 17–18 weeks when the starting treatment was tamoxifen and in 22 weeks when the starting treatment was letrozole. Tumors progressing on tamoxifen remained sensitive to second-line therapy with letrozole (10 μg per day). However, when mice with letrozole-resistant tumors were switched to antiestrogen treatment, tumors did not respond to tamoxifen (100 μg per day) or faslodex (1 mg per day). This suggests that advanced breast cancers treated with letrozole may be insensitive to subsequent second-line hormonal agents. Thus, although letrozole was determined to be an effective second-line treatment option for tumors progressing on tamoxifen, antiestrogen therapy does not appear to be effective for tumors progressing on letrozole. However, response to second-line treatment was observed in a model where tumors that had progressed on letrozole were transplanted to new mice. These tumors had been allowed to grow in the presence of supplemented androstenedione but absence of letrozole. This suggests that resistance to letrozole may be reversible, allowing tumors to respond to subsequent antiestrogens and letrozole. 相似文献
19.
Moon Jae Chung Jeong Youp Park Seungmin Bang Seung Woo Park Si Young Song 《Cancer immunology, immunotherapy : CII》2014,63(9):939-946
Second-line chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer has shown disappointing survival outcomes due to rapid disease progression and performance deterioration. The aim of this phase II trial was to evaluate the efficacy and safety of adoptive immunotherapy using ex vivo-expanded, cytokine-induced killer (CIK) cells in gemcitabine-refractory advanced pancreatic cancer. Patients with advanced pancreatic cancer who showed disease progression during gemcitabine-based chemotherapy were enrolled in this study. For generation of CIK cells, peripheral blood samples were collected from each patient and cultured with anti-CD3 monoclonal antibody and IL-2. Patients received CIK cells intravenously 10 times, every week for 5 weeks and then every other week for 10 weeks. Twenty patients were enrolled between November 2009 and September 2010. The disease control rate was 25 % (4/16 patients). The median progression-free survival (PFS) was 11.0 weeks (95 % CI 8.8–13.2), and the median overall survival (OS) was 26.6 weeks (95 % CI 8.6–44.6). Grade 3 toxicities included general weakness in two patients and thrombocytopenia in one patient. Grade 4 hematologic or non-hematologic toxicity was not observed. Patients showed improvement in pancreatic pain, gastrointestinal distress, jaundice, body image alterations, altered bowel habits, health satisfaction, and sexuality when assessing quality of life (QoL). Adoptive immunotherapy using CIK cells showed comparable PFS and OS to survival data of previous trials that assessed conventional chemotherapies while maintaining tolerability and showing encouraging results in terms of patient QoL in gemcitabine-refractory advanced pancreatic cancer (clinicalTrials.gov number NCT00965718). 相似文献